01 The NASH market is indirectly exposed to supply chain disruptions due to its dependence on pharmaceutical manufacturing, active pharmaceutical ingredients, clinical trial materials, and specialized diagnostic technologies. Disruptions in raw material sourcing, contract manufacturing, logistics, and global distribution networks can delay drug development, regulatory submissions, and commercial product availability, impacting treatment access across multiple regions. Despite these challenges, the market is expected to follow a capacity-constrained recovery, supported by supply chain diversification, increased manufacturing investments, and strengthening pharmaceutical production capabilities.
01 Growing Adoption of Combination Therapies for Improved Disease Management The increasing complexity of NASH treatment is driving the transition from single-drug approaches to combination therapies targeting multiple disease pathways, including inflammation, fibrosis, and metabolic dysfunction. Pharmaceutical companies are advancing combination regimens to improve therapeutic efficacy and patient outcomes while addressing different stages of disease progression. This trend is strengthening clinical development pipelines and expanding treatment possibilities for patients with advanced liver disease.
02 Increasing Integration of Non-invasive Diagnostic Technologies into Clinical Care The growing need for early disease detection is accelerating the transition from liver biopsy toward non-invasive diagnostic tools such as imaging techniques and blood-based biomarkers. Healthcare providers are increasingly adopting these technologies to improve patient identification, monitor disease progression, and support timely treatment decisions. For instance, Echosens' FibroScan is widely used to assess liver fibrosis and steatosis in patients with suspected NASH.
01 The NASH (MASH) market forecasts investments directed toward the development of combination therapies, next-generation metabolic drug candidates, RNA-based therapeutics, biomarker discovery, and non-invasive diagnostic technologies to improve disease detection and treatment outcomes. In July 2025, Madrigal secured a USD 350 million term loan facility with access to an additional USD 150 million delayed-draw facility and up to USD 250 million incremental financing to support commercialization of Rezdiffra and expansion of its MASH pipeline.
01 Advancements in Late Stage Drug Development and Rising Complexity of High Blood-Loss Surgical Procedures Drives Market The advancement of Phase III drug candidates is strengthening confidence in the NASH treatment landscape, driving market demand and investment. Pharmaceutical companies are expanding late-stage clinical programs to develop therapies that target liver fibrosis, inflammation, and metabolic dysfunction, improving future treatment availability. This is accelerating commercialization strategies, strategic collaborations, and manufacturing preparedness across the industry.The increasing volume of complex cardiovascular, transplant, major orthopedic, and aortic surgeries is creating demand for advanced autotransfusion technologies capable of managing substantial intraoperative blood loss. These procedures often require rapid blood recovery and reinfusion to maintain hemodynamic stability while reducing dependence on donor blood supplies. As surgical techniques become more sophisticated and intervention complexity rises, healthcare facilities are investing in specialized blood salvage systems to support efficient perioperative blood management and procedural continuity.
01 Limited Patient Identification and Lack of Disease-specific Treatment Options Restrain Market Expansion The limited diagnosis of NASH due to asymptomatic disease progression and dependence on specialized diagnostic methods restricts the identification of eligible patients for treatment. Many cases remain undetected until advanced stages, reducing treatment uptake and slowing commercialization opportunities for emerging therapies.The absence of multiple approved therapies addressing different stages and mechanisms of NASH limits treatment flexibility and reduces broader clinical adoption. Many emerging therapies focus on specific disease pathways, while patients often require comprehensive management of metabolic conditions, fibrosis progression, and liver inflammation.
01 Expansion of Precision Medicine Approaches and Increasing Adoption of Digital Liver Health Platforms Offer Growth Opportunities to Market Players The increasing use of biomarker-driven patient segmentation creates growth opportunities for pharmaceutical companies developing targeted NASH therapies. Precision medicine approaches can help identify patients based on fibrosis stage, metabolic profile, and disease characteristics, improving treatment selection and clinical outcomes. Companies such as Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are investing in advanced metabolic and liver disease pipelines that support personalized treatment strategies. This opportunity is expected to expand as healthcare providers move toward more individualized NASH management models.The increasing integration of artificial intelligence, digital health platforms, and remote monitoring tools creates growth opportunities for companies developing solutions that improve NASH screening, progression tracking, and patient management. These technologies can support earlier intervention by combining clinical data, imaging results, and metabolic indicators for more efficient disease monitoring. This opportunity is expected to expand as healthcare systems focus on scalable approaches for managing the growing burden of metabolic liver diseases.
01 Balancing Safety and Efficacy Profiles and Integrating NASH Therapies into Existing Metabolic Disease Treatment Pathways Challenges Market Growth The development of NASH therapies requires achieving meaningful improvements in liver fibrosis while maintaining acceptable safety profiles, particularly among patients with obesity, diabetes, and cardiovascular risks. Balancing therapeutic effectiveness with tolerability remains a challenge for companies advancing novel mechanisms. For example, several investigational NASH candidates have faced setbacks due to safety concerns or insufficient efficacy signals during clinical development, affecting confidence in certain treatment approaches.The overlap between NASH, obesity, diabetes, and cardiovascular disorders creates challenges in defining treatment pathways and positioning NASH-specific therapies within existing clinical practices. Healthcare providers need to determine when to initiate liver-directed treatments alongside metabolic disease management, which can slow adoption. This complexity requires companies to generate clinical evidence supporting how NASH therapies complement existing metabolic interventions.
October 2025 Novo Nordisk announced the acquisition of Akero Therapeutics to expand its MASH portfolio by adding efruxifermin (EFX), a Phase III FGF21 analogue targeting MASH with fibrosis.
September 2025 Roche announced a definitive merger agreement to acquire 89bio, strengthening its metabolic and liver disease portfolio through the addition of pegozafermin, a Phase III FGF21 analogue being developed for moderate to severe MASH.